Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 März 2024 - 10:30PM
Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq:
OLMA), a clinical-stage biopharmaceutical company focused on the
discovery, development, and commercialization of targeted therapies
for women’s cancers, today announced that the Company granted stock
options to one new employee to purchase an aggregate of 50,000
shares of the Company's common stock, effective as of March 1,
2024. These awards were approved by the Compensation Committee of
Olema’s Board of Directors and granted under the Company's 2022
Inducement Plan, with a grant date of March 1, 2024, as an
inducement material to the new employees entering into employment
with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options vest over four years, with 25
percent vesting on the first anniversary of the vesting
commencement date for such employee and the remainder vesting in 36
equal monthly installments over the following three years, subject
to the employee being continuously employed by Olema as of such
vesting dates. The stock options have a 10-year term and an
exercise price of $14.80 per share, equal to the last reported sale
price of the Company's common stock as reported by Nasdaq on March
1, 2024. The stock options are subject to the terms of the Olema
Pharmaceuticals, Inc., 2022 Inducement Plan.
Olema is providing this information in
accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema OncologyOlema
Oncology is a clinical-stage biopharmaceutical company committed to
transforming the standard of care and improving outcomes for women
living with cancer. Olema is advancing a pipeline of novel
therapies by leveraging our deep understanding of endocrine-driven
cancers, nuclear receptors, and mechanisms of acquired resistance.
In addition to our lead product candidate, palazestrant (OP-1250),
a proprietary, orally-available complete estrogen receptor (ER)
antagonist (CERAN) and a selective ER degrader (SERD), Olema is
developing a potent KAT6 inhibitor (OP-3136). Olema is
headquartered in San Francisco and has operations in Cambridge,
Massachusetts. For more information, please visit us at
www.olema.com.
Contact:Geoffrey Mogilner, Vice President,
Investor Relations and Communicationsir@olema.com
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Olema Pharmaceuticals (NASDAQ:OLMA)
Historical Stock Chart
Von Mai 2023 bis Mai 2024